Skip to main
SER
SER logo

SER Stock Forecast & Price Target

SER Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Serina Therapeutics Inc. is positioned positively due to the advancements in its pipeline candidates, particularly with the focus on high-value indications, which signifies a potential for considerable market impact. The company's POZ Platform delivery technology enhances drug precision, which could lead to significant competitive advantages over existing treatment options, addressing notable limitations in current biocompatible polymers. Furthermore, the anticipated clinical success of pipeline candidates like SER-270, alongside the growing approval footprint of SER-252, suggests potential long-term upside that is currently unaccounted for in the company's valuation assessments.

Bears say

Serina Therapeutics reported a net loss of $0.64 per share, which significantly exceeds previous estimates, reflecting worsening financial conditions. The company faces multiple fundamental risks, including challenges in advancing its lead candidate, SER-252, through necessary clinical evaluations and regulatory approvals, which are critical for its future revenue potential. Additionally, the projected full-year 2025 net loss has escalated to $2.01, indicating ongoing financial strain and potential dilution risks that may further impact investor sentiment.

SER has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Serina Therapeutics, Inc. (SER) Forecast

Analysts have given SER a Strong Buy based on their latest research and market trends.

According to 2 analysts, SER has a Strong Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Serina Therapeutics, Inc. (SER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.